Abstract. Two patients with metastatic endocrine pancreatic tumours initially responded well to therapy with the long-acting somatostatin analogue SMS 201-995. In the first patient with an insulinoma both the number of hypoglycemic attacks and the increased insulin levels decreased initially, but returned to pretreatment intensity and concentrations within 9 days after the start of therapy with 200\p=n-\300 \g=m\g SMS 201-995 daily. After a short interruption, no effect was observed of re-institution of therapy at a dose of 400 \g=m\g 
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In a few patients with vipomas, glucagonomas and carcinoids, mild worsening of symptoms and increasing tumour-related hormone concentra¬ tions were observed during long-term therapy for over a year with SMS 201-995 (Anderson & Bloom 1986; Kvols et al. 1986 ), but doubling the dose of the analogue reversed these problems in most pa¬ tients (Anderson & Bloom 1986 ).
In the present study we describe 2 patients with a metastatic endocrine pancreatic tumour (one pa- (Kvols et al. 1987) , and in carcinoids (Kvols et al. 1986 ). In some cases evidence was presented of an arrest of tu¬ mour growth or even an actual shrinkage of these tumours (Kvols et al. 1986; Wood et al. 1985) . After the initial positive reports it became gradually clear that during long-term therapy with SMS 201-995, a mild worsening of the symptoms and an in¬ crease in the initially suppressed circulating tu¬ mour-related hormone concentrations occurred in a minority of patients, especially in those with a vipoma or glucagonoma (Anderson & Bloom 1986; Kvols et al. 1987) and less frequently in those with metastatic carcinoids (Kvols et al. 1986 ). However, an increase in the dose of the somatostatin anal¬ ogue resulted in futher clinical improvement and (often incomplete) lowering of hormone levels in most patients (Anderson & Bloom 1986 (Reubi et al. 1987 ).
Actual development of resistance to SMS 201-995 as seen in our second patient were described in 2 vipoma patients (Koelz et al. 1987) . It was con¬ cluded that the need to increase the dose of the analogue might be due to desensitization or per¬ haps progression of tumour growth (Anderson & Bloom 1986; Koelz et al. 1987) . It was also sug¬ gested that the beneficial effect of the somatostatin analogue in some cases of diarrhea might be due to a direct effect on the gut not involving a decrease in the secretion of VIP (Wood et al. 1985) . If this last suggestion is true, beneficial effects of SMS 201-995 might also be expected in patients with severe diarrhea of other causes including cholera.
In the present study we described 2 patients in whom development of resistance to SMS 201-995 occurred within 22 days after starting the anal¬ ogue. This resistance involved both the inhibitory effect on hormone secretion ( (Marki et al. 1982) . It is currently unknown why this desensitization phenomenon or tachyphylaxis to SMS 201-995 therapy in man seems to be confined to endocrine pancreatic tumours (Lamberts 1986 (Kvols et al. 1986 (Kvols et al. , 1987 .
